Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3SBioSTU:83B +0.63%89 3-Year ROIIC % is 275.35 as of Dec. 2025, which is 1903% above its 10-year median of 13.75. GuruFocus rates STU:83B with a GF Score™ of 89/100 and a GF Value™ of €1.41 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 1,322 Biotechnology companies, 3SBio ranks better than 86.99% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
3SBio's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 275.35%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for 3SBio's 3-Year ROIIC % or its related term are showing as below:
STU:83B's 3-Year ROIIC % is ranked better than 86.99% of 1322
companies
in the Biotechnology industry
Industry Median: -4.9
vs STU:83B: 275.35
3SBio (STU:83B) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
3SBio 3-Year ROIIC % Related Terms
3SBio 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for 3SBio's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:83B vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, 3SBio's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
3SBio 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 3SBio's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where 3SBio's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
3SBio (STU:83B) has a 3-Year ROIIC % of 275.35 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on 3SBio and its competitors. This is 1903% above median its historical median of 13.75. Over the past decade, 3SBio's 3-Year ROIIC % has ranged from 8.66 to 275.35. According to the industry distribution chart, 3SBio ranks #172 out of 1322 companies in the Biotechnology industry, placing it in the top 13%.
Is 3SBio's 3-Year ROIIC % too high?
3SBio's current 3-Year ROIIC % of 275.35 is 1903% above median its 10-year median of 13.75. Over the past 10 years, this metric has ranged from a low of 8.66 to a high of 275.35. Based on the distribution chart, 3SBio ranks #172 out of 1322 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, 3SBio has a GF Score™ of 89/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 3SBio's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, 3SBio ranks #172 out of 1322 companies for 3-Year ROIIC %. This places 3SBio in the top 13% of its industry — outperforming the majority of peers. Historically, 3SBio's own 3-Year ROIIC % has ranged from 8.66 to 275.35 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on 3SBio and its competitors. 3SBio's current 3-Year ROIIC % is 275.35, which is 1903% above median its own 10-year median of 13.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3SBio stock overvalued right now?
Based on GuruFocus' analysis, 3SBio (STU:83B) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.41, compared to a current price of €1.86 — trading 32% above its estimated fair value. The current 3-Year ROIIC % is 275.35, which is 1903% above median its 10-year median of 13.75. 3SBio's overall GF Score™ is 89/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For 3SBio (STU:83B), the current 3-Year ROIIC % is 275.35 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 3SBio (STU:83B) Overvalued in 2026?
Based on GuruFocus' analysis, 3SBio stock appears to be overvalued.
The current stock price of €1.86 is trading 32% above its estimated GF Value™ of €1.41.
GuruFocus considers 3SBio to be Significantly Overvalued.
Key valuation signals for STU:83B:
3-Year ROIIC %: 275.35 (1903% above median its 10-year median of 13.75)
GF Value™: €1.41 vs. price of €1.86 (32% above fair value)
No single metric tells the full story. See the STU:83B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
3SBio Inc is an investment holding company. It is a primary biotechnology company. The company is principally engaged in the development, production, marketing and sale of biopharmaceutical products in the People's Republic of China. The group has only one operating segment. It has presence in Chinese mainland, USA, Other countries/regions. The majority of revenue comes from USA. The core commercialized products of the group include several bio-pharmaceutical drugs, namely, TPIAO, recombinant human erythropoietin (rhEPO) products EPIAO and SEPO, Yisaipu and Cipterbin, and a small molecule drug, Mandi series of minoxidil drugs.
89GF Score
Get the complete analysis for STU:83B
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:83B has been successfully added to your 
